Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Global transcriptome analysis of IL-33, IL-25, IL-13, TSLP, IL-4, and IL-9 overexpression in mouse spleen

ABSTRACT: IL-33 is an inflammatory cytokine contributing to asthma, Chronic Obstructive Pulmonary Disease (COPD), and autoimmune diseases. Although recent studies suggest that IL-33 can induce the generation of autoantibodies, the role of IL-33 on B cell maturation and tolerance is poorly understood. Here, by inducing systemic overexpression of IL-33 in mice, we show that this cytokine induces the IL-5 and CD4 T cell-dependent accumulation of plasmablasts and plasma cells of all isotypes in the spleen, and leads to an increased antibody production. IL-33 also disrupts splenic architecture and elevates autoantibody production, indicating a break in peripheral tolerance. Consistently, elevated levels of IL-33 exacerbate autoantibody production, kidney damage, and decrease survival in a mouse model of lupus. Additionally, intranasal delivery of IL-33 in mice exposed to house dust mite extract (HDM) increases autoantibodies in the lung. Notably, blocking IL-33 reduced the autoantibodies generated during HDM exposure, indicating that HDM-induced autoantibody production is IL-33 dependent. Thus, our findings implicate IL-33 in the break of peripheral B cell tolerance, opening new therapeutic avenues for the treatment of infection, COPD and autoimmune conditions.

ORGANISM(S): Mus musculus

PROVIDER: GSE313261 | GEO | 2025/12/10

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The IL-33 and IL-4Rα blocking antibodies, itepekimab and dupilumab, modulate distinct and common inflammatory mediators in asthma - mouse data

Project description:Biologics that target IL-4Ra or IL-33 pathways have demonstrated clinical efficacy in asthma and chronic obstructive pulmonary disease (COPD), highlighting the importance of IL-4, IL-13 and IL-33 in respiratory diseases. Despite this, there are limited studies that link preclinical models to human disease and evaluate disease biology in the setting of clinical trials. To address these gaps, we evaluated transcriptional, cellular and pathophysiological processes driven by IL-4/ IL-13 and IL-33 using human innate cells in vitro, a mouse model of airway inflammation and a Bronchial Allergen Challenge (BAC) in house dust mite (HDM)-sensitized individuals with mild asthma. Using the HDM mouse model of airway inflammation, we show that blockade of either IL-4Ra or IL-33 at the peak of type 2 (T2) inflammation leads to inhibition of airway inflammation and remodeling. While the combination of dupilumab and itepekimab was not additive, blockade of both IL-33 and IL-4Ra in a severe, late-phase mixed T1/T2 inflammation reduced all measured parameters. Consistent with some of these observations in mice, blocking either IL-33 or IL-4Ra in the context of T2 airway inflammation suppressed sputum gene expression in individuals with mild persistent asthma post-BAC. Overall, these results highlight that IL-33 and IL-4/IL-13 are key drivers of airway inflammation and remodeling and provide insight into the differences in targeting IL-4Ra or IL-33 pathways in asthma independently or in combination.

2025-12-03 | GSE282861 | GEO

The IL-33 and IL-4Rα blocking antibodies, itepekimab and dupilumab, modulate distinct and common inflammatory mediators in asthma - human mast cell and eosinophil data

2025-12-03 | GSE282860 | GEO

Activator protein transcription factors coordinate human IL-33 expression from non-canonical promoters in chronic airway disease

Project description:Interleukin-33 (IL-33) is a cytokine central to type-2 immune pathology in chronic airway disease. This cytokine is abundantly expressed in the respiratory epithelium and increased in disease, but how this is regulated is undefined. Here we show IL-33 is expressed from multiple promoters in human chronic obstructive pulmonary disease (COPD) and non-canonical promoters mediate production of alternatively spliced isoforms. Transposase-accessible chromatin sequencing (ATAC-seq) performed on cell lines with distinct IL-33 expression levels demonstrated chromatin accessibility as a control point for IL-33 expression. We further discovered that phorbol esters activate non-canonical IL-33 promoters through protein kinase C in airway cells. Transcription factor (TF) binding arrays combined with RNA interference revealed Activator Protein transcription factors as the downstream effectors of non-canonical IL-33 promoter activation. In support of a role for Activator Protein-2 family members in COPD pathogenesis, we found both TFAP2A and TFAP2C are upregulated in disease, with phosphorylated TFAP2C localized to IL-33-positive airway basal cells in COPD lung tissue. This study defines how pioneer transcription factors associated with stemness can drive non-canonical IL-33 promoters and alternative splicing patterns in airway epithelial progenitors. Our work reveals a novel approach for targeting the IL-33 pathway to promote the development of new therapeutics for COPD.

2024-04-03 | GSE249720 | GEO

Quantitative phosphoproteomic analysis of IL-33 mediated signaling

Project description:Interleukin-33 (IL-33) is a novel member of the IL-1 family of cytokines that plays diverse roles in the regulation of immune responses. IL-33 exerts its effects by binding to a heterodimeric receptor complex consisting of interleukin-1 receptor like 1 (IL1RL1) and an accessory receptor protein IL-1RAcP resulting in the production and release of proinflammatory cytokines. A detailed understanding of the signaling pathways activated by IL-33 remains elusive. To elucidate IL-33 mediated signaling, we performed a global quantitative phosphoproteomic analysis using stable isotope labeling by amino acids in cell culture. Employing anti-phosphotyrosine antibodies and titanium dioxide-based enrichment strategies, we identified 6,207 phosphorylation sites mapping to 2,013 phosphoproteins of which more than 185 phosphosites are regulated by IL-33 stimulation. Our findings will greatly expand the understanding of IL-33 signaling and provide novel therapeutic targets for IL-33/IL-33R-associated diseases in humans.

2015-01-29 | PXD000984 | Pride

Illumina Humanmethylation450k array analysis of human lymph node stromal cells during the earliest phases of rheumatoid arthritis

Project description:Lymph node stromal cells (LNSCs) are an important lymphoid tissue cellular type that regulates the immune response and maintain peripheral tolerance. In rheumatoid arthritis, break of tolerance and formation of autoantibodies occurs years before arthritis. Studies in mice have shown lymph nodes activation before the onset of arthritis. We hypothesize that malfunctioning of LNSCs leads to a microenvironment where immune responses are not properly controlled leading to activation of (autoreactive) lymphocytes and the production of autoantibodies. Here we studied human LNSCs and search for differentially methylated genes between RA versus healthy using Illumina human methylation arrays in order to identify new epigenetic targets.

2019-07-01 | E-MTAB-8085 | biostudies-arrayexpress

RNA-Seq of human lymph node stromal cells during the earliest phases of rheumatoid arthritis

Project description:Lymph node stromal cells (LNSCs) are an important lymphoid tissue cellular type that regulates the immune response and maintain peripheral tolerance. In rheumatoid arthritis, break of tolerance and formation of autoantibodies occurs years before arthritis. Studies in mice have shown lymph nodes activation before the onset of arthritis. We hypothesize that malfunctioning of LNSCs leads to a microenvironment where immune responses are not properly controlled leading to activation of (autoreactive) lymphocytes and the production of autoantibodies. Here we studied human LNSCs and search for differentially expressed genes between RA at risk or RA versus healthy using RNA sequencing in order to identify new therapeutic targets.

2019-07-01 | E-MTAB-7897 | biostudies-arrayexpress

Transcriptome analysis of acute IL-33 or chronic HDM activated murine lung ILC2s

Project description:We have identified CD25high and CD25low ILC2 subsets in various mouse models of airway inflammation. Transcriptome analysis of acute IL-33 (CD25High) or chronic HDM (CD25Low) activated murine lung ILC2s suggests functional differences between these two ILC2 populations.

2020-05-13 | GSE99780 | GEO

Allergen sensitization stratifies IL-31 production by memory T cells in atopic dermatitis patients.

Project description:The role of allergen sensitization in IL-31 production by T cells and specifically in the clinical context of atopic dermatitis (AD) has not been characterized. The response to house dust mite (HDM) in purified memory T cells cocultured with epidermal cells from AD patients (n=58) and control subjects (n=11) was evaluated. AD-associated cytokines from culture supernatants, plasma proteins and mRNA expression from cutaneous lesions were assessed and related with the clinical features of the patients. HDM-induced IL-31 production by memory T cells defined two subsets of AD patients according to the presence or absence of IL-31 response. Patients in the IL-31 producing group showed a more inflammatory profile, and increased HDM-specific (sp) and total IgE levels compared to the IL-31 non-producing group. A correlation between IL-31 production and patient’s pruritus intensity, plasma CCL27 and periostin was detected. When the same patients were analyzed based on HDM-specific (sp) IgE and total IgE levels, an increased IL-31 in vitro response, as well as type 2 markers in plasma and cutaneous lesions, was found in patients with sp IgE levels > 100 kUA/L and total IgE levels > 1000 kU/L. The IL-31 response by memory T cells was restricted to the cutaneous lymphocyte-associated antigen (CLA)+ T-cell subset. IgE sensitization to HDM allows stratifying IL-31 production by memory T cells in AD patients and relating it to particular clinical phenotypes of the disease.

2023-03-06 | GSE226073 | GEO

CXCR5+PD-1+CD8+ T cells are a novel T helper cell sublineage and are negatively regulated by Stat5 [scRNA-Seq]

Project description:Many autoimmune diseases are characterized by the production of autoantibodies. The current view is that CD4+ Tfh cells are the main subset regulating autoreactive B cells. Here, we discover a distinct novel CXCR5+PD1+ Tfh subset of CD8+ T cells whose development and function are negatively regulated by Stat5. These CD8+ Tfh cells regulate the GC B cell response and control autoantibody production. Deficiency of Stat5 in CD8+ T cells leads to an increase of CD8+ Tfh cells, resulting in the breakdown of B cell tolerance and autoantibody production. CD8+ Tfh share similar gene signatures with CD4+ Tfh and require CD40L/CD40 and TCR/MHCI interactions to deliver help to B cells. Our study highlights the diversity of follicular T cell subsets that contribute to the breakdown of B-cell tolerance

2019-08-30 | GSE136641 | GEO

CXCR5+PD-1+CD8+ T cells are a distinct sublineage of CD8+ Tfh cells and Stat5 suppresses the expression of the Tfh-specific genes in CXCR5+PD-1+CD8+ T cells [RNA-Seq]

Project description:Many autoimmune diseases are characterized by the production of autoantibodies. The current view is that CD4+ Tfh cells are the main subset regulating autoreactive B cells. Here, we discover a novel CXCR5+PD1+ Tfh subset of CD8+ T cells whose development and function are negatively regulated by Stat5. These CD8+ Tfh cells regulate the GC B cell response and control autoantibody production. Deficiency of Stat5 in CD8+ T cells leads to an increase of CD8+ Tfh cells, resulting in the breakdown of B cell tolerance and autoantibody production. CD8+ Tfh cells share similar gene signatures with CD4+ Tfh cells and require CD40L/CD40 and TCR/MHCI interactions to deliver help to B cells. Our study highlights the diversity of follicular T cell subsets that contribute to the breakdown of B-cell tolerance

2019-08-30 | GSE136640 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data